Evidence map›Paper›PMID 41684755›Full record

ArticleKardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery2025

Lobectomy offers higher incidence of up-staging in patients with T1a-c non-small cell lung carcinomas: Is completion lobectomy necessary?

Gizem Özçıbık Işık, Burcu Kılıç, Ezel Erşen, Mehmet K Kaynak, Hasan V Kara, Akif Turna

Abstract read
In one paragraph

Article in Kardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Gizem Özçıbık IşıkDepartment of Thoracic Surgery, Yedikule Chest Diseases and Thoracic Surgery Education and Research Hospital, Istanbul, Turkey.
Burcu KılıçDepartment of Thoracic Surgery, School of Medicine, Istanbul University Cerrahpasa, Istanbul, Turkey.
Ezel ErşenDepartment of Thoracic Surgery, School of Medicine, Istanbul University Cerrahpasa, Istanbul, Turkey.
Mehmet K KaynakDepartment of Thoracic Surgery, School of Medicine, Istanbul University Cerrahpasa, Istanbul, Turkey.
Hasan V KaraDepartment of Thoracic Surgery, School of Medicine, Istanbul University Cerrahpasa, Istanbul, Turkey.
Akif TurnaDepartment of Thoracic Surgery, School of Medicine, Istanbul University Cerrahpasa, Istanbul, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Completion lobectomy is defined as the excision of the remaining lobe following a previous sublobar resection. While it is considered a salvage option in selected cases, its impact on nodal staging and overall survival remains unclear in patients with early-stage non-small cell lung cancer (NSCLC). Aim: This study aimed to evaluate the effect of completion lobectomy on nodal upstaging and overall survival in patients with T1a-c NSCLC. Material and methods: A retrospective analysis was conducted on 477 patients with pathologically confirmed NSCLC and tumor size ≤ 3 cm, who underwent sublobar resection ( Results: The lobectomy group demonstrated significantly higher rates of N1 nodal involvement compared to the sublobar group ( Conclusions: Lobectomy results in higher pathological upstaging in cT1N0M0 NSCLC. Completion lobectomy is feasible and safe when nodal upstaging occurs following segmentectomy, though it may not confer a survival advantage in cT1aN0 cases.

Indexed as

completion lobectomynon-small cell lung cancersublobar resectionup-staging

Identifiers

PMID41684755
PMCPMC12892178

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.